FLAb: Benchmarking deep learning methods for antibody fitness prediction

Author:

Chungyoun MichaelORCID,Ruffolo JeffreyORCID,Gray JeffreyORCID

Abstract

AbstractThe successful application of machine learning in therapeutic antibody design relies heavily on the ability of models to accurately represent the sequence-structure-function landscape, also known as the fitness landscape. Previous protein bench-marks (including The Critical Assessment of Function Annotation [33], Tasks Assessing Protein Embeddings [23], and FLIP [6]) examine fitness and mutational landscapes across many protein families, but they either exclude antibody data or use very little of it. In light of this, we present the Fitness Landscape for Antibodies (FLAb), the largest therapeutic antibody design benchmark to date. FLAb currently encompasses six properties of therapeutic antibodies: (1) expression, (2) thermosta-bility, (3) immunogenicity, (4) aggregation, (5) polyreactivity, and (6) binding affinity. We use FLAb to assess the performance of various widely adopted, pretrained, deep learning models for proteins (IgLM [28], AntiBERTy [26], ProtGPT2 [11], ProGen2 [21], ProteinMPNN [7], and ESM-IF [13]); and compare them to physics-based Rosetta [1]. Overall, no models are able to correlate with all properties or across multiple datasets of similar properties, indicating that more work is needed in prediction of antibody fitness. Additionally, we elucidate how wild type origin, deep learning architecture, training data composition, parameter size, and evolutionary signal affect performance, and we identify which fitness landscapes are more readily captured by each protein model. To promote an expansion on therapeutic antibody design benchmarking, all FLAb data are freely accessible and open for additional contribution athttps://github.com/Graylab/FLAb.

Publisher

Cold Spring Harbor Laboratory

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. A comprehensive overview of recent advances in generative models for antibodies;Computational and Structural Biotechnology Journal;2024-12

2. AI-accelerated therapeutic antibody development: practical insights;Frontiers in Drug Discovery;2024-09-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3